pulmonary arterial hypertension PAH
Conditions
Interventions
None listed
Sponsors
Arai Yoko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed with PAH and prescribed PAH-targeted drug at the same calendar month in the index period, and claimed another PAH diagnosis during the period from the month following the index to the final follow-up period (with or without prescription of PAH-targeted drug) 2. Aged more than 18 years at the index date 3. At least 12 months of continuous registration before the index month (including the index month) (Baseline period) 4. At least 24 months of continuous registration after the index month (Follow-up period) (Note: For secondary objectives, change the follow-up periods to 6-month and 12 month)
Exclusion criteria
Exclusion criteria: 1. Diagnosed with HIV, portal hypertension, schistosomiasis, CTEPH, or PPHN during baseline period 2. History of lung transplantation surgery during baseline period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To understand current clinical practice and disease burden among PAH patients during 24-month follow-up period. For the above purposes, we will analyze PAH patients in real-world using the JMDC claims database. - Demographic and clinical characteristics at baseline - Diagnosis procedure - Treatment patterns - Comorbidity - Adherence to medication - Clinical worsening - HCRU and associated medical costs | — |
Secondary
| Measure | Time frame |
|---|---|
| To understand current clinical practice and disease burden among PAH patients during 6- and 12-month follow-up period. For the above purposes, we will analyze PAH patients in real-world. - Demographic and clinical characteristics at baseline - Diagnosis procedure - Treatment patterns - Comorbidity - Adherence to medication - Clinical worsening - HCRU and associated medical costs | — |
Contacts
Public ContactIchiro Tazaki
MSD K.K
Outcome results
None listed